HIMS Stock Price Today (April 2026) — Hims & Hers Health, Inc. Analysis & Key Metrics 2026-04-02
Hims & Hers Health, Inc. (HIMS) is trading at $19.16, down 3.45% today (as of April 2026). The stock continues to show early recovery signs above the short-term average, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $24.15 (26.1% upside).
- Volatility remains elevated (69.38% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (28.40% YoY) alongside significant competitive pressures.
HIMS Stock Analysis: Key Metrics & Valuation (April 2026)
Concise, actionable data for investors
Hims & Hers Health, Inc. - Historical Price & Volume
Market Cap
Enterprise Value: $4.91B
P/E Ratio
Forward P/E: 11.58
Revenue Growth
Year over Year
Analyst Target
+26.1% upside potential
Key Investor Questions About HIMS
What investors need to know before buying
Based on current market data, HIMS presents a neutral technical setup with caution warranted fundamentals.
- Technicals say: Neutral (RSI 42.77)
- Fundamentals say: Caution warranted (high leverage concerns)
HIMS's growth trajectory depends on its ability to expand within the Drug Manufacturers - Specialty & Generic sector while managing margin pressures.
- Future growth will depend on performance in core Drug Manufacturers - Specialty & Generic operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for HIMS investors include debt exposure and competitive dynamics in the Drug Manufacturers - Specialty & Generic industry.
- $1.12B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Drug Manufacturers - Specialty & Generic.
52-Week Trading Range
Over the past year, HIMS stock traded between $13.74 and $70.43—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 69.38% annualized volatility and β=2.61, the stock exhibits high sensitivity to market moves—making HIMS suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Novo Nordisk Obesity And Diabetes Moves Tested Against Weak Share Performance
Novo Nordisk has introduced a higher dose 7.2 mg version of Wegovy at a lower price than a key rival GLP-1, aiming to sharpen its position in obesity care. The company has renewed its partnership with Hims & Hers Health to distribute obesity medications through direct to consumer channels, expanding access and reach. Following recent US FDA approval, Novo Nordisk is launching once weekly basal insulin Awiqli as a new option in diabetes treatment. For investors watching CPSE:NOVO B, these...
Hims & Hers price target slashed amid GLP-1 transition
Bank of America lowered its 2026 price target for Hims & Hers (NYSE:HIMS) to $21 from $23, citing peer multiple compression and near-term earnings pressures. Shares of Hims & Hers traded hands at about $20 on Wednesday, down almost 39% so far this year. The firm reiterated a...
Hims & Hers Health's Shift to Branded GLP-1s to Weigh on Margins, BofA Securities Says
Hims & Hers Health (HIMS) faces near-term margin pressure as it pivots to branded GLP-1 from compoun
New Derivative Income ETFs Aren’t Worth the Risks
There are now a host of funds that use options to generate income from an individual stock. Here’s how they work—and why individual investors would be wise to steer clear.
The $190 Billion ‘Diabesity’ Market Is Set to Explode. Lilly and Novo Face These Stock Catalysts.
The recent fixation on weight-loss drugs, a catchall term referring to GLP-1 medications like Wegovy and Zepbound, has brought Eli Lilly and Novo Nordisk squarely into the limelight. The combined market for both indications—chronic weight management and diabetes—is projected to be enormous. Morgan Stanley forecasts a “diabesity” total addressable market in the neighborhood of $190 billion in 2035.
Hims & Hers Health, Inc. (HIMS) Stock Dips While Market Gains: Key Facts
In the closing of the recent trading day, Hims & Hers Health, Inc. (HIMS) stood at $19.5, denoting a -4.08% move from the preceding trading day.
Hims & Hers Health (HIMS) Is Up 8.3% After Expanding Novo Nordisk GLP-1 Partnership And Launching New Weight-Loss Membership - Has The Bull Case Changed?
In late March 2026, Hims & Hers Health, Inc. announced a renewed collaboration with Novo Nordisk to offer a broad range of FDA-approved GLP-1 medications, including Wegovy injections and the only FDA-approved Wegovy weight loss pill, alongside a new weight-loss membership program starting at US$39 for the first month and US$149 thereafter, with medication priced separately from US$149 a month. This move expands Hims & Hers’ role in prescription weight management by pairing access to branded...
Hims & Hers Health and Fortune Brands Innovation have been highlighted as Zacks Bull and Bear of the Day
Lam Research's dominance in chip equipment fuels strong growth and rising estimates, but rich valuation and technical setup leave investors weighing timing.
3 Sectors to Buy While They're Down and 1 to Walk Away From
Jeff Clark and Andy Swan share three beaten-down sectors with contrarian upside and one popular sector to avoid, plus specific stock picks in financials, healthcare, and software.
Hims & Hers (HIMS) Taps Into $200-Billion Weight Loss Market, Soars 6%
Hims & Hers Health Inc. (NYSE:HIMS) is one of the 10 Stocks With Unexpected Gains. Hims & Hers bounced back by 6.22 percent on Monday to close at $20.33 apiece, as investors positioned their second-quarter portfolios backed by optimism over its rekindled partnership with Novo Nordisk to jointly capitalize on the $200 billion obesity treatment […]
Frequently Asked Questions
Common investor questions about Hims & Hers Health, Inc.
Hims & Hers Health, Inc. (HIMS) is currently trading at $19.16. The RSI (14-day) is at 42.8, indicating neutral territory. Wall Street analysts have a consensus "hold" recommendation. The mean analyst price target of $24.15 implies 26.1% upside from current levels. Volatility is high at 69.4% annualized, meaning significant price swings are common. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Hims & Hers Health, Inc. (HIMS): The trailing P/E ratio is 37.53, which is above the market average, indicating investors are pricing in higher growth expectations. The forward P/E is 11.58, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 1.71, near 1.0, suggesting roughly fair value relative to growth. Price-to-Book is 8.04. Price-to-Sales is 1.86. Valuation should be compared to Drug Manufacturers - Specialty & Generic industry peers for context, as different sectors trade at different multiples.
Based on 13 analysts covering HIMS, the consensus price target is $24.15. This represents a 26.1% upside from the current price of $19.16. The range spans from a low target of $16.00 to a high target of $30.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "hold". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Hims & Hers Health, Inc. (HIMS) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Hims & Hers Health, Inc. (HIMS) investors include: 1. High volatility (69.4% annualized)—the stock can experience significant daily price swings. 2. Elevated debt levels (D/E ratio of 207.16) which could pressure margins in a rising rate environment. 3. Elevated short interest (45.2% of float) suggests significant bearish sentiment. 4. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 5. Drug Manufacturers - Specialty & Generic sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Hims & Hers Health, Inc.'s (HIMS) current debt and financial health profile: Total debt stands at $1.12B. The debt-to-equity ratio is 207.16, which is high and could pose financial risk if earnings decline or borrowing costs increase. The current ratio is 1.90, indicating strong short-term liquidity. The quick ratio is 1.51. The company holds $577.49M in cash and equivalents. Free cash flow is positive at $110.51M, providing a cushion for debt servicing and shareholder returns.